Aminopeptidase N (APN/CD13) as a target molecule for scirrhous gastric cancer - 17/09/16
, Daisuke Fujiwara a, Naoya Sakuragi b, Kazuyoshi Yanagihara d, Yoshimi Iwanuma a, Yoshiaki Kajiyama aBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 10 |
| Iconographies | 4 |
| Vidéos | 0 |
| Autres | 0 |
Summary |
Background |
Scirrhous gastric cancer is associated with peritoneal dissemination and advanced lymph node metastasis from an early stage, and the prognosis is still poor. In this study, we aimed to analyze candidate molecules for targeted therapy of scirrhous gastric cancer. We searched for molecules/metabolic activity that might be predominantly expressed in a subpopulation of scirrhous gastric cancer cells and might function as cancer stem cell markers.
Results |
For this purpose, we investigated the expression of various cell surface markers and of aldehyde dehydrogenase (ALDH) activity. These analyses showed that the scirrhous gastric cancer cell lines HSC-58 and HSC-44PE heterogeneously expressed CD13, while CD44, CDCP1, EpCAM and ABCG2 were expressed uniformly. Moreover, 10% of the total HSC-58 cell population expressed ALDH enzyme activity. A subpopulation of cells strongly positive for ALDH also expressed high levels of CD13, both of which are known as cancer stem cell markers. HSC-58 cells expressing high levels of CD13 showed lower sensitivity to a cancer drug cisplatin than cells with low levels of CD13. In contrast, CD13-high subpopulation of HSC-58 was more sensitive to an aminopeptidase N inhibitor bestatin. In terms of antibody-drug therapy, anti-CD13-immunotoxin was highly cytotoxic towards HSC-58 cells and was more cytotoxic than anti-EpCAM-immunotoxin.
Conclusion |
These data suggest that CD13 is a suitable cell surface candidate for targeted antibody-drug therapy of scirrhous gastric cancer.
Le texte complet de cet article est disponible en PDF.Plan
Vol 40 - N° 4
P. 494-503 - septembre 2016 Retour au numéro
Article précédent
- Sulfasalazine, a therapeutic agent for ulcerative colitis, inhibits the growth of CD44v9+ cancer stem cells in ulcerative colitis-related cancer
- Ryo Seishima, Koji Okabayashi, Osamu Nagano, Hirotoshi Hasegawa, Masashi Tsuruta, Masayuki Shimoda, Kaori Kameyama, Hideyuki Saya, Yuko Kitagawa
- The efficacy of tyrosine kinase inhibitor dasatinib on colonic mucosal damage in murine model of colitis
- Güray Can, Süleyman Ayvaz, Hatice Can, ?hsan Karabo?a, Selim Demirta?, Hasan Ak?it, Bülent Y?lmaz, U?ur Korkmaz, Mevlüt Kurt, Turan Karaca
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?